Abstract:552 Background: Muscle-invasive bladder cancer (MIBC) is characterized by an overall poor prognosis with a 5-year overall survival (OS) of ~50%. Radical cystectomy (RC) with cisplatin-based neoadjuvant chemotherapy (NAC) has demonstrated improved survival in eligible patients and is the current guideline-recommended treatment; however, NAC is underutilized in the real world. The characterization of NAC-treated patients as well as their clinical outcomes in routine practice warrants continued investigation. The objective of this study is to describe the demographic and clinical characteristics, neoadjuvant treatment patterns, and clinical outcomes of patients with MIBC undergoing RC with NAC. Methods: A retrospective cohort study was conducted among adult patients (≥18 years) with MIBC (T2–T4aN0M0, T1–T4aN1M0) diagnosed between 1/1/2016 and 12/31/2021, who received NAC followed by RC, selected from the Syapse Learning Health Network. Patients with another primary tumor ≤3 years prior to MIBC diagnosis, prior partial cystectomy, or prior neoadjuvant radiation were excluded. Patients were followed from NAC initiation (index date) until end of the study period (12/31/2022) or death, whichever occurred first. The analyses included descriptive statistics of demographic and clinical characteristics, NAC treatment pattern, and pathologic complete response (pCR), defined as pT0N0 per pathology reports. Kaplan–Meier analysis was used to describe OS. Results: A total of 140 patients with MIBC met the eligibility criteria of this study (median age 67; 73% male; 90% white; 82% current or former smokers), with a median follow-up of 34 months. Almost all (98%) patients had de novo MIBC and 99% had urothelial histology. At diagnosis, most patients (83%) were staged with T2N0M0 disease; the remaining patients had T1–T4aN1M0 (9.3%) or T3/4N0M0 (7.9%) disease. Median time from MIBC diagnosis to RC was 5 months and median (IQR) NAC treatment duration was 68 days (44-74). The most commonly used NAC regimen was cisplatin + gemcitabine (62.9%), followed by cisplatin + doxorubicin + methotrexate + vinblastine (30.0%). Among patients with pCR data (n=136), 29% achieved pCR. During follow-up, 21% of patients died, and median OS was not reached. Survival rates (95% CI) at 2 and 3 years were 83.8% (77.8–90.2%) and 79.7% (73–87.1%), respectively. Conclusions: Cisplatin-based NAC was widely utilized, with cisplatin + gemcitabine being the most commonly administered regimen. Approximately a third of patients in this neoadjuvant treated RC cohort achieved pCR. Future studies should investigate intermediate or surrogate outcomes in MIBC such as disease-free, event-free, or metastatic-free survival when mature follow-up data is unavailable. Longer follow-up is required to monitor long-term outcomes such as median overall survival.

Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?

Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation

Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes

Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy

Outcomes with neoadjuvant chemotherapy in bladder-preserving treatment for MIBC.

Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.

Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study

Characteristics, treatment patterns, and clinical outcomes of patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer in the real world.

Impact of upper tract urothelial carcinoma history on patients with non-muscle-invasive bladder cancer undergoing intravesical chemotherapy

Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?

Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer

The effect of postoperative pathological findings related to the eligibility of adjuvant immunotherapy on oncologic outcomes in patients with locally advanced urothelial cancer.

Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis

Non-Surgical Bladder-Sparing Multimodal Management in Organ-Confined Urothelial Carcinoma of the Urinary Bladder: A Population-Based Analysis

Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status

Differences in Cancer-Specific Mortality after Trimodal Therapy for T2N0M0 Bladder Cancer according to Histological Subtype

Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer

Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis